MPLT
MapLight Therapeutics, Inc.
$29.46
+5.18%
$1.3B
No data for this timeframe.
Vol
Market Cap$1.3B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders6 funds
Inst. Value$19.1M
Inst. Activity6 buys / 0 sells
Insider Activity4B / 41S
Insider Net $-$9.4M
SEC Reports11
Press Releases2
Recent Activity
May 19, 2026
clinical_trial_readout
Results Pending: ML-004 (IR)/(ER) tablet (Phase 2) — Completed 70d ago
Trial: ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
Sponsor: MapLight Thera
May 19, 2026
SEC
CEO Christopher Kroeger sold $3.21M of MPLT stock on May 18, four days after the company reported Q1 2026 results (net l
CLUSTER — Impact 5/10
May 18, 2026
Insider
Kroeger Christopher A. sold 118,037 shares
Chief Executive Officer @ $27.19 ($3.2M)
May 12, 2026
SEC
Five MapLight insiders, including the CEO, CFO, CSO, and CMO, sold a total of ~$937K in open-market sales over a 7-day w
CLUSTER — Impact 3/10
May 11, 2026
Insider
Hanson Kristopher sold 284 shares
General Counsel @ $27.61 ($7.8K)
May 11, 2026
Insider
Kroeger Christopher A. sold 342 shares
Chief Executive Officer @ $27.57 ($9.4K)
May 7, 2026
SEC
MapLight Therapeutics insiders sold a combined $1.3M in open-market sales over a 7-day window, including the CEO, CFO, C
CLUSTER — Impact 5/10
Inst.
VANGUARD GROUP INC — NEW
869,668 shares ($15.3M)
Price Targets
$38.70
+32.2% upside
Strong Buy
Current $29.27
Low $30.00
Median $36.50
High $48.00
10 analysts
$30.00
$48.00
Analyst Ratings
5Strong Buy
10Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 2, 2026 | Stifel | MAINTAIN | Buy → Buy |
| May 28, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 27, 2026 | UBS | INITIATE | Buy |
| May 21, 2026 | Craig-Hallum | INITIATE | Buy |
| May 4, 2026 | HC Wainwright & Co. | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.42 ▼ -24.9% | $-1.47 — $-1.33 | 6 | |
| Next Q | $-1.26 ▼ -16.1% | $-1.35 — $-1.06 | 6 | |
| Current FY | $-5.16 ▼ -19.0% | $-5.51 — $-4.65 | 72% YoY | 6 |
| Next FY | $-4.28 ▼ -14.6% | $-5.19 — $-3.36 | 17% YoY | 6 |
Latest Reports
BEARISH
CLUSTER
5/10
CEO Christopher Kroeger sold $3.21M of MPLT stock on May 18, four days after the company reported Q1 2026 results (net l
May 19, 2026
NEUTRAL
CLUSTER
3/10
Five MapLight insiders, including the CEO, CFO, CSO, and CMO, sold a total of ~$937K in open-market sales over a 7-day w
May 12, 2026
NEUTRAL
Press
4/10
MapLight Therapeutics announced completion of enrollment in the Phase 2 ZEPHYR trial for ML-007C-MA in schizophrenia (30
May 1, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $15.3M | NEW |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $2.4M | NEW |
| BANK OF AMERICA CORP | $664.3K | NEW |
| MORGAN STANLEY | $407.9K | NEW |
| WELLS FARGO & COMPANY/MN | $328.2K | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 18, 2026 | Kroeger Christopher | SELL | $3.2M |
| May 11, 2026 | Hanson Kristopher | SELL | $7.8K |
| May 11, 2026 | Kroeger Christopher | SELL | $9.4K |
| May 8, 2026 | Kroeger Christopher | SELL | $814.1K |
| May 7, 2026 | Kroeger Christopher | SELL | $423.6K |
6 institutional holders with $19.1M total value (1,088,728 shares) as of 2025-Q4. Top holders: VANGUARD, CHARLES, BANK. Net buying activity: 6 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 869,668 | $15.3M | 79.9% | NEW |
| 2 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 138,427 | $2.4M | 12.7% | NEW |
| 3 | BANK OF AMERICA CORP /DE/ | 37,820 | $664.3K | 3.5% | NEW |
| 4 | MORGAN STANLEY | 23,222 | $407.9K | 2.1% | NEW |
| 5 | WELLS FARGO & COMPANY/MN | 18,687 | $328.2K | 1.7% | NEW |
| 6 | FMR LLC | 904 | $15.9K | 0.1% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | NEW | — | 869,668 | — | $15.3M | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 138,427 | — | $2.4M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEW | — | 37,820 | — | $664.3K | 2025-Q4 |
| MORGAN STANLEY | NEW | — | 23,222 | — | $407.9K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | NEW | — | 18,687 | — | $328.2K | 2025-Q4 |
| FMR LLC | NEW | — | 904 | — | $15.9K | 2025-Q4 |
10 unique insiders with 45 transactions. Net insider value: -$9.4M ($693.8K bought, $10.1M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 18, 2026 | Kroeger Christopher A. | Chief Executive Officer | SELL | 118,037 | $27.19 | $3.2M |
| May 11, 2026 | Hanson Kristopher | General Counsel | SELL | 284 | $27.61 | $7.8K |
| May 11, 2026 | Kroeger Christopher A. | Chief Executive Officer | SELL | 342 | $27.57 | $9.4K |
| May 8, 2026 | Kroeger Christopher A. | Chief Executive Officer | SELL | 29,624 | $27.48 | $814.1K |
| May 7, 2026 | Kroeger Christopher A. | Chief Executive Officer | SELL | 14,880 | $28.47 | $423.6K |
| May 7, 2026 | Foff Erin Pennock | Chief Medical Officer | SELL | 4,321 | $28.52 | $123.2K |
| May 7, 2026 | Lillie James Woodruff | Chief Scientific Officer | SELL | 721 | $28.28 | $20.4K |
| May 6, 2026 | Kroeger Christopher A. | Chief Executive Officer | SELL | 8,098 | $28.04 | $227.1K |
| May 6, 2026 | Foff Erin Pennock | Chief Medical Officer | SELL | 8,152 | $28.04 | $228.6K |
| May 6, 2026 | Lillie James Woodruff | Chief Scientific Officer | SELL | 8,390 | $28.04 | $235.3K |
| May 6, 2026 | Setia Vishwas | Chief Financial Officer | SELL | 8,496 | $28.04 | $238.2K |
| May 5, 2026 | Kroeger Christopher A. | Chief Executive Officer | SELL | 9,544 | $28.12 | $268.4K |
| May 5, 2026 | Foff Erin Pennock | Chief Medical Officer | SELL | 9,645 | $28.12 | $271.2K |
| May 5, 2026 | Lillie James Woodruff | Chief Scientific Officer | SELL | 10,132 | $28.12 | $284.9K |
| May 5, 2026 | Setia Vishwas | Chief Financial Officer | SELL | 9,935 | $28.12 | $279.4K |
| May 4, 2026 | Kroeger Christopher A. | Chief Executive Officer | SELL | 9,136 | $27.50 | $251.2K |
| May 4, 2026 | Hanson Kristopher | General Counsel | SELL | 9,030 | $27.50 | $248.3K |
| May 4, 2026 | Foff Erin Pennock | Chief Medical Officer | SELL | 9,180 | $27.50 | $252.4K |
| May 4, 2026 | Lillie James Woodruff | Chief Scientific Officer | SELL | 9,250 | $27.50 | $254.4K |
| May 4, 2026 | Setia Vishwas | Chief Financial Officer | SELL | 4,803 | $27.36 | $131.4K |
| Apr 28, 2026 | GILLIS JONATHAN | CAAO and PAO | SELL | 17,235 | $30.33 | $522.7K |
| Apr 27, 2026 | GILLIS JONATHAN | CAAO and PAO | SELL | 7,914 | $28.94 | $229.0K |
| Apr 27, 2026 | Kreitzer Anatol | Chief Discovery Officer | SELL | 8,346 | $28.96 | $241.7K |
| Apr 16, 2026 | Lillie James Woodruff | Chief Scientific Officer | SELL | 686 | $27.01 | $18.5K |
| Apr 16, 2026 | Hanson Kristopher | General Counsel | SELL | 73 | $27.01 | $2.0K |
| Apr 16, 2026 | Foff Erin Pennock | Chief Medical Officer | SELL | 288 | $27.01 | $7.8K |
| Apr 16, 2026 | Setia Vishwas | Chief Financial Officer | SELL | 29 | $27.01 | $783.29 |
| Apr 16, 2026 | Kroeger Christopher A. | Chief Executive Officer | SELL | 2,477 | $27.01 | $66.9K |
| Apr 15, 2026 | GILLIS JONATHAN | CAAO and PAO | SELL | 3,590 | $26.61 | $95.5K |
| Apr 15, 2026 | Malenka Robert C. | Director | SELL | 8,593 | $26.90 | $231.2K |
| Apr 15, 2026 | Setia Vishwas | Chief Financial Officer | SELL | 2,806 | $26.87 | $75.4K |
| Apr 15, 2026 | Foff Erin Pennock | Chief Medical Officer | SELL | 2,044 | $26.84 | $54.9K |
| Apr 15, 2026 | Hanson Kristopher | General Counsel | SELL | 1,529 | $26.80 | $41.0K |
| Apr 15, 2026 | Kroeger Christopher A. | Chief Executive Officer | SELL | 9,135 | $26.93 | $246.0K |
| Apr 15, 2026 | Lillie James Woodruff | Chief Scientific Officer | SELL | 1,730 | $26.82 | $46.4K |
| Apr 15, 2026 | Kreitzer Anatol | Chief Discovery Officer | SELL | 3,316 | $26.61 | $88.2K |
| Feb 24, 2026 | Malenka Robert C. | Director | SELL | 736 | $18.15 | $13.4K |
| Feb 23, 2026 | Malenka Robert C. | Director | SELL | 10,788 | $18.39 | $198.4K |
| Feb 20, 2026 | Pavlov George | Director | BUY | 9,920 | $17.86 | $177.2K |
| Feb 20, 2026 | Malenka Robert C. | Director | SELL | 2,195 | $18.03 | $39.6K |
| Feb 19, 2026 | Pavlov George | Director | BUY | 4,422 | $17.57 | $77.7K |
| Feb 18, 2026 | Pavlov George | Director | BUY | 10,658 | $17.48 | $186.3K |
| Feb 11, 2026 | Malenka Robert C. | Director | SELL | 241 | $18.00 | $4.3K |
| Feb 10, 2026 | Garnett Timothy John | Director | BUY | 14,124 | $17.89 | $252.7K |
| Feb 10, 2026 | Malenka Robert C. | Director | SELL | 6,622 | $18.12 | $120.0K |
| Feb 5, 2026 | Kroeger Christopher A. | Chief Executive Officer | A | 23,145 | $0.00 | $0.00 |
| Feb 5, 2026 | Kroeger Christopher A. | Chief Executive Officer | A | 93,955 | $0.00 | $0.00 |
| Feb 5, 2026 | Foff Erin Pennock | Chief Medical Officer | A | 13,360 | $0.00 | $0.00 |
| Feb 5, 2026 | Foff Erin Pennock | Chief Medical Officer | A | 54,240 | $0.00 | $0.00 |
| Feb 5, 2026 | Hanson Kristopher | General Counsel | A | 7,730 | $0.00 | $0.00 |
11 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 0 mixed, 8 neutral. Avg impact: 3.4/10.
BEARISH
CLUSTER
5/10
CEO Christopher Kroeger sold $3.21M of MPLT stock on May 18, four days after the company reported Q1
May 19, 2026
NEUTRAL
CLUSTER
3/10
Five MapLight insiders, including the CEO, CFO, CSO, and CMO, sold a total of ~$937K in open-market
May 12, 2026
BEARISH
CLUSTER
5/10
MapLight Therapeutics insiders sold a combined $1.3M in open-market sales over a 7-day window, inclu
May 7, 2026
NEUTRAL
144
2/10
Officer Christopher Kroeger filed Form 144 to sell 236,470 shares (~$7.3M) under a 10b5-1 plan adopt
May 4, 2026
NEUTRAL
144
3/10
Officer Lillie James Woodruff filed a Form 144 to sell 52,428 shares of common stock valued at appro
May 4, 2026
NEUTRAL
144
3/10
Officer Jonathan Gillis filed a Form 144 indicating intent to sell 69,835 shares of MapLight Therape
Apr 27, 2026
BEARISH
CLUSTER
6/10
Multiple executives at MapLight Therapeutics, including CEO Christopher Kroeger and CFO Vishwas Seti
Apr 17, 2026
NEUTRAL
144
3/10
Jonathan Gillis, an officer of MapLight Therapeutics, filed a Form 144 to notify intent to sell up t
Apr 15, 2026
NEUTRAL
144
3/10
Robert C. Malenka, a director of MapLight Therapeutics, filed a Form 144 notifying intent to sell 8,
Apr 15, 2026
NEUTRAL
144
2/10
Christopher Kroeger, an officer of MapLight Therapeutics, filed a Form 144 to notify intent to sell
Apr 15, 2026
NEUTRAL
144
2/10
Lillie James Woodruff, an officer of MapLight Therapeutics (MPLT), filed a Form 144 notifying intent
Apr 15, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 16 analysts: 5 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$38.70 mean target
+32.2% upside
Strong Buy (1.18)
$30.00 Low
$48.00 High
| Metric | Value |
|---|---|
| Current Price | $29.27 |
| Target Low | $30.00 |
| Target Mean | $38.70 |
| Target Median | $36.50 |
| Target High | $48.00 |
| # Analysts | 10 |
| Recommendation | Strong Buy (1.18) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.42 | $-1.47 | $-1.33 | — | -24.9% | — | $0.0B | — | 6 |
| Next Q 2026-09-30 |
$-1.26 | $-1.35 | $-1.06 | — | -16.1% | — | $0.0B | 0.0% | 6 |
| Current FY 2026-12-31 |
$-5.16 | $-5.51 | $-4.65 | 72.2% | -19.0% | — | $0.0B | 0.0% | 6 |
| Next FY 2027-12-31 |
$-4.28 | $-5.19 | $-3.36 | 17.0% | -14.6% | — | $0.0B | 0.0% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.415 | |
| 7d ago | $-1.322 | -0.093 |
| 30d ago | $-1.133 | -0.282 |
| 60d ago | $-0.987 | -0.428 |
| 90d ago | $0.000 | -1.415 |
7 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 6 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 2, 2026 | Stifel | MAINTAIN | Buy | Buy |
| May 28, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 27, 2026 | UBS | INITIATE | — | Buy |
| May 21, 2026 | Craig-Hallum | INITIATE | — | Buy |
| May 4, 2026 | HC Wainwright & Co. | INITIATE | — | Buy |
| Apr 8, 2026 | Needham | INITIATE | — | Buy |
| Apr 7, 2026 | TD Cowen | INITIATE | — | Buy |
| Mar 19, 2026 | Canaccord Genuity | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 10 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% | |
| Mar 1, 2026 | 5 | 4 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 5 | 4 | 1 | 0 | 0 | 90% | |
| Jan 1, 2026 | 5 | 4 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 20, 2026
Clinical Trial
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
Phase Phase 2 — COMPLETED
May 19, 2026
clinical_trial_readout
Results Pending: ML-004 (IR)/(ER) tablet (Phase 2) — Completed 70d ago
Trial: ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
Sponsor: MapLight Therapeutics
Phase: Phase 2 | Completed: 2026-03-10
Con
May 1, 2026
fda
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
<p>SAN FRANCISCO and BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company
Mar 26, 2026
earnings
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
<p>SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical compa
Mar 23, 2026
short_interest
FTD: MPLT — 70,309 shares ($1.2M) failed to deliver
Settlement: 20260323, Price: $17.56, FTD Value: $1,234,626.04, MAPLIGHT THERAPEUTICS INC COM
Mar 2, 2026
earnings_calendar
MPLT Q4 2025 Earnings Scheduled — 2026-03-02
Feb 24, 2026
short_interest
FTD: MPLT — 68,938 shares ($1.3M) failed to deliver
Settlement: 20260224, Price: $18.30, FTD Value: $1,261,565.4, MAPLIGHT THERAPEUTICS INC COM
Feb 17, 2026
short_interest
FTD: MPLT — 46,055 shares ($0.8M) failed to deliver
Settlement: 20260217, Price: $17.22, FTD Value: $793,067.1, MAPLIGHT THERAPEUTICS INC COM